Mar­ket­ingRx roundup: My­ovant, Pfiz­er launch first Myfem­bree ads; IPG Health gath­ers med­comm agen­cies

My­ovant Sci­ences and Pfiz­er de­buted the first na­tion­al TV com­mer­cial for Myfem­bree, their co-mar­ket­ed drug ap­proved to treat uter­ine fi­broids.

The TV ad fea­tures a Black mom with a busy fam­i­ly life — a hus­band, two daugh­ters, a dog, friends, ex­er­cise, work — that as she says is “not al­ways pic­ture per­fect — plus I’m deal­ing with bleed­ing from uter­ine fi­broids.”

Black women are 2-3 times more like­ly to de­vel­op uter­ine fi­broids, more like­ly to get them at a younger age, and have more of them with more symp­toms com­pared to white women, ac­cord­ing to the Black Women’s Health Im­per­a­tive. The rate of hos­pi­tal­iza­tion for fi­broids is three times high­er for Black women than white women, the health and well­ness ad­vo­ca­cy group says.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.